{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T11:00:45Z","timestamp":1773054045843,"version":"3.50.1"},"reference-count":71,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.bbmt.2014.07.020","type":"journal-article","created":{"date-parts":[[2014,7,23]],"date-time":"2014-07-23T16:05:04Z","timestamp":1406131504000},"page":"1828-1834","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Calcineurin Inhibitor\u2013Free Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Brief-Course Sirolimus Following Reduced-Intensity Peripheral Blood Stem Cell Transplantation"],"prefix":"10.1016","volume":"20","author":[{"given":"Scott R.","family":"Solomon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Sanacore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2249-8589","authenticated-orcid":false,"given":"Stacey","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kent","family":"Holland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence E.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asad","family":"Bashey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2014.07.020_bib1","series-title":"Thomas' hematopoietic cell transplantation","author":"Appelbaum","year":"2004"},{"key":"10.1016\/j.bbmt.2014.07.020_bib2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0140-6736(84)92009-9","article-title":"How does bone-marrow transplantation cure leukaemia?","volume":"324","author":"Gale","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2014.07.020_bib3","first-page":"18","article-title":"Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy","volume":"111","author":"Champlin","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2014.07.020_bib4","first-page":"242","article-title":"Nonmyeloablative stem cell transplantation: lessons from the first decade of clinical experience","volume":"3","author":"Shimoni","year":"2004","journal-title":"Curr Hematol Rep"},{"key":"10.1016\/j.bbmt.2014.07.020_bib5","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2004-05-1947","article-title":"Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age","volume":"105","author":"Alyea","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.020_bib6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/annonc\/mdf010","article-title":"Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens","volume":"13","author":"Bertz","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2014.07.020_bib7","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/sj.leu.2404037","article-title":"Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity","volume":"20","author":"Shimoni","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2014.07.020_bib8","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1083-8791(00)70007-3","article-title":"Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial","volume":"6","author":"Chao","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.07.020_bib9","first-page":"1690","volume":"96","author":"Locatelli","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.020_bib10","first-page":"2062","article-title":"Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors","volume":"96","author":"Nash","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.020_bib11","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1182\/blood-2005-04-1614","article-title":"Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation","volume":"106","author":"Pavletic","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.020_bib12","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/sj.bmt.1704594","article-title":"Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes","volume":"34","author":"Uberti","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.07.020_bib13","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1182\/blood-2002-01-0011","article-title":"Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial","volume":"100","author":"Flowers","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.020_bib14","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood.V100.9.3128","article-title":"Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study","volume":"100","author":"Mohty","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.020_bib15","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nm915","article-title":"CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation","volume":"9","author":"Edinger","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.bbmt.2014.07.020_bib16","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1182\/blood.V99.10.3493","article-title":"The infusion of ex\u00a0vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethality","volume":"99","author":"Taylor","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.020_bib17","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1172\/JCI17702","article-title":"Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia","volume":"112","author":"Trenado","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.bbmt.2014.07.020_bib18","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1182\/blood-2008-02-140277","article-title":"In\u00a0vivo-activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease","volume":"112","author":"Zhao","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.020_bib19","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1182\/blood-2006-02-003996","article-title":"High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT","volume":"108","author":"Rezvani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.020_bib20","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1182\/blood-2005-06-2529","article-title":"Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD","volume":"107","author":"Rieger","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.020_bib21","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1182\/blood-2005-03-1257","article-title":"Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease","volume":"106","author":"Zorn","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.020_bib22","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/sj.bmt.1705628","article-title":"Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+CD25+ FoxP3+ T cells","volume":"39","author":"Coenen","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.07.020_bib23","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1182\/blood-2006-01-0329","article-title":"Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production","volume":"108","author":"Zeiser","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.020_bib24","doi-asserted-by":"crossref","first-page":"ra157","DOI":"10.1126\/scitranslmed.3006960","article-title":"Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide","volume":"5","author":"Kanakry","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bbmt.2014.07.020_bib25","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.07.020_bib26","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease, I: Diagnosis and Staging Working Group Report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.07.020_bib27","first-page":"360","article-title":"Nonparametric estimation from incomplete observations","volume":"84","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.bbmt.2014.07.020_bib28","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/sj.bmt.1703271","article-title":"Statistical methods for the analysis and presentation of the results of bone marrow transplants, part 2: regression modeling","volume":"28","author":"Klein","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.07.020_bib29","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A\u00a0class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"10.1016\/j.bbmt.2014.07.020_bib30","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.2012.44.3523","article-title":"T-cell\u2013replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation","volume":"31","author":"Bashey","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.07.020_bib31","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2011-03-344853","article-title":"Alternative donor transplantation after reduced-intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts","volume":"118","author":"Brunstein","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.020_bib32","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1182\/blood-2009-11-251595","article-title":"High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease","volume":"115","author":"Luznik","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.020_bib33","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.07.020_bib34","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","article-title":"Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide","volume":"8","author":"O'Donnell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.07.020_bib35","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.bbmt.2012.06.019","volume":"18","author":"Solomon","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.07.020_bib36","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1053\/bbmt.2002.v8.pm11939602","article-title":"Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation","volume":"8","author":"Luznik","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.07.020_bib37","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood.V98.12.3456","article-title":"Durable engraftment of major histocompatibility complex\u2013incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide","volume":"98","author":"Luznik","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.020_bib38","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0009-9120(98)00045-9","article-title":"Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression","volume":"31","author":"Sehgal","year":"1998","journal-title":"Clin Biochem"},{"key":"10.1016\/j.bbmt.2014.07.020_bib39","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1182\/blood-2004-10-3932","article-title":"Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells","volume":"105","author":"Battaglia","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.020_bib40","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1182\/blood.V100.3.1084","article-title":"Rapamycin inhibits macropinocytosis and mannose receptor\u2013mediated endocytosis by bone marrow\u2013derived dendritic cells","volume":"100","author":"Hackstein","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.020_bib41","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1182\/blood-2002-11-3370","article-title":"Rapamycin inhibits IL-4\u2013induced dendritic cell maturation in\u00a0vitro and dendritic cell mobilization and function in\u00a0vivo","volume":"101","author":"Hackstein","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.020_bib42","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00007890-200301150-00025","article-title":"Rapamycin impairs antigen uptake of human dendritic cells","volume":"75","author":"Monti","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2014.07.020_bib43","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0041-1345(00)02141-2","article-title":"Rapamycin reduces expression of fibrosis-associated genes in an experimental model of renal ischaemia reperfusion injury","volume":"33","author":"Jain","year":"2001","journal-title":"Transplant Proc"},{"key":"10.1016\/j.bbmt.2014.07.020_bib44","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/S0016-5085(99)70406-3","article-title":"Rapamycin inhibits hepatic stellate cell proliferation in\u00a0vitro and limits fibrogenesis in an in\u00a0vivo model of liver fibrosis","volume":"117","author":"Zhu","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbmt.2014.07.020_bib45","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1200\/JCO.2008.17.7279","article-title":"Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning","volume":"26","author":"Armand","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.07.020_bib46","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2004-06-2494","article-title":"Antileukemic activity of rapamycin in acute myeloid leukemia","volume":"105","author":"Recher","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.020_bib47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2362.2007.01892.x","article-title":"Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia","volume":"38","author":"Sillaber","year":"2008","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.bbmt.2014.07.020_bib48","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1073\/pnas.080068597","article-title":"The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus\u2013transformed B lymphocytes in\u00a0vitro and in\u00a0vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders","volume":"97","author":"Majewski","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbmt.2014.07.020_bib49","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1182\/blood-2007-01-069294","article-title":"Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis","volume":"110","author":"Marty","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.020_bib50","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/bmt.2013.60","article-title":"Sirolimus and post-transplant Cy synergistically maintain mixed chimerism in a mismatched murine model","volume":"48","author":"Fitzhugh","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.07.020_bib51","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1182\/blood-2008-07-169342","article-title":"Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation","volume":"112","author":"Cutler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.020_bib52","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/bmt.2011.104","article-title":"Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation","volume":"47","author":"Johnston","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.07.020_bib53","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/j.1875-9114.2012.01034.x","article-title":"Possible correlation of sirolimus plasma concentration with sinusoidal obstructive syndrome of the liver in patients undergoing myeloablative allogeneic hematopoietic cell transplantation","volume":"32","author":"Kiel","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bbmt.2014.07.020_bib54","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.bbmt.2010.09.017","article-title":"Prophylaxis with sirolimus and tacrolimus\u00a0+\/- antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation","volume":"17","author":"Rosenbeck","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.07.020_bib55","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2014.07.020_bib56","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/blood.V94.2.455","article-title":"Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation","volume":"94","author":"Ringden","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.020_bib57","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/sj.bmt.1701510","article-title":"A\u00a0randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies","volume":"22","author":"Vigorito","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.07.020_bib58","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2004-01-0200","article-title":"Duration of immunosuppressive treatment for chronic graft-versus-host disease","volume":"104","author":"Stewart","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.020_bib59","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1038\/sj.leu.2404822","article-title":"Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome","volume":"21","author":"Corradini","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2014.07.020_bib60","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.2005.03.1765","article-title":"Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors","volume":"24","author":"Hegenbart","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.07.020_bib61","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1182\/blood-2001-11-0107","article-title":"Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation","volume":"100","author":"Robinson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.020_bib62","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3324\/haematol.2011.045757","volume":"97","author":"Sureda","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2014.07.020_bib63","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1200\/JCO.2007.11.1641","article-title":"Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival","volume":"26","author":"Valcarcel","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.07.020_bib64","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/sj.leu.2404471","article-title":"Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma","volume":"21","author":"Haritunians","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2014.07.020_bib65","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/blood-2002-01-0189","article-title":"Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin","volume":"101","author":"Decker","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.020_bib66","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2004-11-4513","article-title":"A\u00a0rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein \u03b2 and NF-\u03baB activity in Hodgkin and anaplastic large cell lymphomas","volume":"106","author":"Jundt","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.020_bib67","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2141.2006.06210.x","article-title":"Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab","volume":"134","author":"Wanner","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2014.07.020_bib68","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.07.020_bib69","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3324\/haematol.2011.053173","article-title":"A\u00a0multicenter phase II trial (SAKK 36\/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma","volume":"97","author":"Renner","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2014.07.020_bib70","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1200\/JCO.2010.29.2813","article-title":"Temsirolimus has activity in non\u2013mantle cell non-Hodgkin's lymphoma subtypes: the University of Chicago Phase II Consortium","volume":"28","author":"Smith","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.07.020_bib71","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/leu.2010.226","article-title":"A\u00a0phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma","volume":"25","author":"Witzig","year":"2011","journal-title":"Leukemia"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879114004467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879114004467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:48:49Z","timestamp":1761058129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879114004467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":71,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S1083879114004467"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2014.07.020","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Calcineurin Inhibitor\u2013Free Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Brief-Course Sirolimus Following Reduced-Intensity Peripheral Blood Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2014.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}